TICH 2 Trial
Start date:October 2013 End date:
February 2018 Co-ordinated by:
University of Nottingham Main trial site:
http://tich-2.org
Tranexamic Acid for Hyperacute Primary IntraCerebral Haemorrhage
Aim
To assess whether tranexamic acid is safe and reduces death and dependency after hyperacute (within 8 hours of onset) spontaneous intracerebral haemorrhage.
Trial Design
A phase III prospective pragmatic double blind randomised placebo controlled trial
Chief Investigator
Dr Nikola Sprigg (Medical expert) Clinical Associate Professor, University of Nottingham
Principal Investigator
Professor Rustam Al-Shahi Salman, Professor of clinical neurology, University of Edinburgh & NHS Lothian
Local lead in ED
Dr Matt Reed is the local contact for recruitment of ED patients into the study.
Research Team
- EMERGE Research team
- Stroke Research Group
Eligibility criteria (summary)
Patients who present to the ED within 8 hours of acute spontaneous intracerebral haemorrhagic stroke.
Further information
For more information please refer to main trial website
Research Team
Dr Matt Reed
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
Bernadette Gallagher
Senior Research Nurse
More EMERGE Trials
Assisting in identifying patients with Humeral shaft fractures in the ED by screening.
Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.
HU-FIX Trial
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.